Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

  title={Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT},
  author={Gilles Edan and Ludwig Kappos and Xavier Montalban and Chris H. Polman and M. S. Freedman and H. -J. Hartung and David H. Miller and Frederik Barkhof and Jennifer Herrmann and Vivian Lanius and Brigitte Stemper and Christoph Pohl and Rupert Sandbrink and Dirk Pleimes},
  booktitle={Journal of neurology, neurosurgery, and psychiatry},
OBJECTIVE To examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS). METHODS In the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg or placebo subcutaneously every other day. After 2 years or diagnosis of clinically definite MS (CDMS), all patients were offered open-label IFNB1b treatment for a maximum duration of 5 years… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 24 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
17 Citations
21 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 17 extracted citations


Publications referenced by this paper.
Showing 1-10 of 21 references

Evidence for a two - stage disability progression in multiple sclerosis

  • RP Kinkel, C Kollman, P O’Connor
  • Brain
  • 2010

Similar Papers

Loading similar papers…